Mostrando 2 resultados de: 2
Coronavirus disease 2019 in Latin American patients with multiple sclerosis
OtherAbstract: Patients with multiple sclerosis (MS) who present coronavirus disease 2019 (COVID-19) are of particuPalabras claves:covid-19, Multiple Sclerosis, ocrelizumab, pandemic, rituximabAutores:Carcamo Rodriguez C., Carmisciano L., Ciampi E., Edgar Patricio Correa, Fragoso Y.D., Gomes S., Pimentel M.L.V., Ponzano M., Santos G.A.C., Schiavetti I., Sormani M.P., Steinberg J., Treviño-Frenk I., Vecino M.C.A., Vrech C., Winckler T.C.A.Fuentes:scopusPractical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
OtherAbstract: Abstract: The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin AmePalabras claves:Alemtuzumab, Biological drugs, Biosimilar, Glatiramoids, Interferon beta, Multiple Sclerosis, Natalizumab, ocrelizumabAutores:Carcamo Rodriguez C., Carra A., Ciampi E., Duran Quiroz J.C., Edgar Patricio Correa, Fragoso Y.D., García J.R., Guerra C., Macias M.A., Novarro N., Oehninger Gatti C., Orozco G., Rodriguez V., Steinberg J., Vizcarra D.Fuentes:scopus